ReviewAmerican journal of physiology. Heart and circulatory physiology2012
The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.
Review in American journal of physiology. Heart and circulatory physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 1 synthesis or guideline pooled it, 273 citations in OpenAlex.
- The relationship between adipose tissue RAAS activity and the risk factors of prediabetes: a systematic review and meta-analysis.Adipocyte · 2023Pooled it
- A comprehensive approach to lifestyle intervention based on a calorie-restricted diet ameliorates liver fat in overweight/obese patients with NAFLD: a multicenter randomized controlled trial in China.Nutrition journal · 2024Trial
- Temporal changes in soluble angiotensin-converting enzyme 2 associated with metabolic health, body composition, and proteome dynamics during a weight loss diet intervention: a randomized trial with implications for the COVID-19 pandemic.The American journal of clinical nutrition · 2021Trial
- Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome.The Annals of thoracic surgery · 2017Trial
- Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial.Diabetologia · 2016Trial
- ACE2 downregulation contributes to adverse cardiovascular and reproductive outcomes in female mice on high-fat diet.American journal of physiology. Heart and circulatory physiology · 2026Article
- Empagliflozin Attenuates Cardiac Dysfunction in Rat Model of Metabolic Syndrome: Evaluating Role of the Cardiac Renin-Angiotensin System.Biomedicines · 2026Article
- Association of cumulative systemic inflammation response index and all-cause mortality in adult with cardiovascular-kidney-metabolic syndrome stages 0-2: a prospective cohort study.BMC cardiovascular disorders · 2026Article
- Relationship between triglyceride-glucose (TyG) index and anthropometric indices of obesity in patients with type-2 diabetes mellitus attending Dessie Comprehensive Specialized Hospital, Northeast Ethiopia.Scientific reports · 2026Article
- Epigenetic Modulation of the ACE System Underlies the Slow Aerobic Muscle Phenotype and Metabolic Exercise Response.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Role of adipocyte angiotensinogen or angiotensin type 1a receptors in the development of diet-induced atherosclerosis or angiotensin II-induced abdominal aortic aneurysms.JVS-vascular science · 2026Article
- Impact of systemic immune inflammation index and systemic inflammation response index on all-cause and cardiovascular mortality in cardiovascular-kidney-metabolic syndrome.European journal of medical research · 2025Article
- Triglyceride-glucose index: an independent risk factor for all-cause mortality in critically ill aneurysmal subarachnoid hemorrhage patients- a retrospective analysis of the MIMIC-IV database.Neurosurgical review · 2025Article
- Molecular dissection of the role of ACE2 in glucose homeostasis.Physiological reviews · 2025Review
- Independent and combined associations of high-density lipoprotein cholesterol-modified triglyceride-glucose index with all-cause and cardiovascular mortality in patients with acute decompensated heart failure.Frontiers in endocrinology · 2025Article
- Minoxidil and nebivolol restore aortic elastic fiber homeostasis in diabetic mice via potassium channel activation.Frontiers in physiology · 2025Article
- Sex and Age Differences in the Impact of Metabolic Syndrome on Heart Failure Development.Metabolites · 2024Review
- Maternal Dietary Strategies for Improving Offspring Cardiovascular-Kidney-Metabolic Health: A Scoping Review.International journal of molecular sciences · 2024Article
- The Impact of Metabolic Syndrome on Heart Failure in Young Korean Population: A Nationwide Study.Metabolites · 2024Article
- Association between systemic immune-inflammation index and cardiovascular-kidney-metabolic syndrome.Scientific reports · 2024Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The renin-angiotensin system (RAS) is an important therapeutic target in the treatment of hypertension. Obesity has emerged as a primary contributor to essential hypertension in the United States and clusters with other metabolic disorders (hyperglycemia, hypertension, high triglycerides, low HDL cholesterol) defined within the metabolic syndrome. In addition to hypertension, RAS blockade may also serve as an effective treatment strategy to control impaired glucose and insulin tolerance and dyslipidemias in patients with the metabolic syndrome. Hyperglycemia, insulin resistance, and/or specific cholesterol metabolites have been demonstrated to activate components required for the synthesis [angiotensinogen, renin, angiotensin-converting enzyme (ACE)], degradation (ACE2), or responsiveness (angiotensin II type 1 receptors, Mas receptors) to angiotensin peptides in cell types (e.g., pancreatic islet cells, adipocytes, macrophages) that mediate specific disorders of the metabolic syndrome. An activated local RAS in these cell types may contribute to dysregulated function by promoting oxidative stress, apoptosis, and inflammation. This review will discuss data demonstrating the regulation of components of the RAS by cholesterol and its metabolites, glucose, and/or insulin in cell types implicated in disorders of the metabolic syndrome. In addition, we discuss data supporting a role for an activated local RAS in dyslipidemias and glucose intolerance/insulin resistance and the development of hypertension in the metabolic syndrome. Identification of an activated RAS as a common thread contributing to several disorders of the metabolic syndrome makes the use of angiotensin receptor blockers and ACE inhibitors an intriguing and novel option for multisymptom treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.